成果報告書詳細
管理番号20130000000293
タイトル*平成24年度中間年報「環境・医療分野の国際研究開発・実証プロジェクト フランスにおける国際共同研究開発・実証事業 ヒト化動物を用いた次世代型がん領域創薬支援システムの研究開発・実証」(公益財団法人実験動物中央研究所)
公開日2014/8/20
報告書年度2012 - 2012
委託先名公益財団法人実験動物中央研究所
プロジェクト番号P11017
部署名バイオテクノロジー・医療技術部
和文要約
英文要約Title: International Research and Development, and Demonstration Projects in Environmental and Medical Technologies. Research & Development for generating new system of anti-cancer drug discovery with humanized experimental animals (FY2012 - FY2013) FY2012 Annual Report

In first year, two major themes have been conducted, titled "Establishing genetically modified NOG mice as experimental animal" and "Establishing humanized model with modified NOG mice". Establishing genetically modified NOG mice as experimental animal; it has been succeeded to produce a hundred TK-NOG mice per a month. Concerning to NOG-hIL-2, we are now preparing to distribute to Oncodesign, France. Moreover, we have accomplished establishing NOG-hIL-15 and NOG-HLA/DdA2 lines and conducting microbial cleaning. In addition, frozen embryos of these mice have been preserved. Regular microbial monitoring (virus, bacteria, and parasite; total 30 tests) has been performed to guarantee the quality of these mice in terms of microbial cleanliness. Establishing humanized model with modified NOG mice; In vivo model to measure ADCC activity of antibody drug for cancer has been examined with hIL-2-NOG. It has been revealed that NK cells differentiated from engrafted human stem cell shows tumor rejection. The result implies the differentiated NK cells are functional. Besides, direct effect of antibody drugs, such as Rituximab (against Daudi cell) and Herceptin (against 4-1ST cell), were detected on the assay. It might be critical to select appropriate tumor cell lines for the ADCC test. For taking steps forward, thirty male of TK-NOG mice were distributed to Oncodesign, France, on March 18th in 2013.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る